Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Frederic Pinguet"'
Autor:
Clément Carbasse, Fanny Leenhardt, William Jacot, Caroline Perrier, Frederic Pinguet, Marie Viala
Publikováno v:
British Journal of Clinical Pharmacology. 88:3370-3377
Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer.This noninterventional, retrospective study was a real-life assessment of dose adaptation for si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d76fb2a63ece2acef03c2586366059b
https://doi.org/10.1111/bcp.15285
https://doi.org/10.1111/bcp.15285
Autor:
Aatmani Anne, Tu Duy Khiem-El, Adeline, Champagne-Danielou, Jean-Marie, Reimund, Laurence, Beretz, Frédéric, Pinguet
Publikováno v:
In Le Pharmacien Hospitalier 2007 42(171):200-207
Autor:
Dominique Charlety, Melanie Brignone, Delphine Exinger, Isabelle Borget, Olivier Chinot, Benedicte Lahille, Frederic Pinguet, P. Tilleul, S. Taillibert, Martine Billard, Danielle Prebay, Sophie Gensollen, Valerie Bertholle, Yasmine Hassani, Stéphane Pedeboscq, Christelle Labrande, Stéphanie Cartalat
Publikováno v:
Pharmacoepidemiology and Drug Safety. 21:828-834
Context Temozolomide (TMZ) is approved for the treatment of high-grade gliomas such as glioblastoma (GBM) multiforme and refractory anaplastic astrocytoma, but it is also used in indications not mentioned in the summary of product characteristics (SP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97812a3096389ba566e73bcd6c673455
https://doi.org/10.1002/pds.3233
https://doi.org/10.1002/pds.3233
Autor:
Damien, Pouessel, Stephane, Culine, Catherine, Becht, Gilles, Romieu, Michel, Fabbro, Marc, Ychou, Didier, Cupissol, Frederic, Pinguet
Publikováno v:
Anticancer research. 23(3C)
The prognosis of patients with carcinoma of unknown primary remains poor with an expected median survival of 6 to 12 months. We evaluated the activity of a chemotherapy regimen combining gemcitabine and docetaxel in patients who primarily failed cisp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4e271968e950d84753682b68caf8a7a5
https://pubmed.ncbi.nlm.nih.gov/12926116
https://pubmed.ncbi.nlm.nih.gov/12926116
Autor:
Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, Litaty Mbatchi, André van Kuilenburg, Christine Bobin-Dubigeon, Fabienne Thomas, Etienne Chatelut, Jean-Louis Merlin, Frédéric Pinguet, Christophe Ferrand, Judith Meijer, Alexandre Evrard, Laurence Llorca, Gilles Romieu, Philippe Follana, Thomas Bachelot, Loic Chaigneau, Xavier Pivot, Véronique Dieras, Rémy Largillier, Mireille Mousseau, Anthony Goncalves, Henri Roché, Jacques Bonneterre, Véronique Servent, Nadine Dohollou, Yann Château, Emmanuel Chamorey, Jean-Pierre Desvignes, David Salgado, Jean-Marc Ferrero, Gérard Milano
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0175998 (2017)
Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The g
Externí odkaz:
https://doaj.org/article/e851b305e66844848f3f60697e611308
Publikováno v:
Biomolecules, Vol 9, Iss 11, p 668 (2019)
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The discovery of several oncogenic driver mutations in patients with NSCLC has allowed the development of personalized treatments based on these specific molecular alt
Externí odkaz:
https://doaj.org/article/f188f3bea55a44d3ba9c4b3db23932ef